Auckland UniServices Revenue and Competitors
Estimated Revenue & Valuation
- Auckland UniServices's estimated annual revenue is currently $33M per year.
- Auckland UniServices's estimated revenue per employee is $112,200
Employee Data
- Auckland UniServices has 294 Employees.
- Auckland UniServices grew their employee count by 5% last year.
Auckland UniServices's People
| Name | Title | Email/Phone |
|---|
Auckland UniServices Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $12.1M | 119 | 7% | N/A | N/A |
#2 | $28.9M | 258 | 7% | N/A | N/A |
#3 | $5.2M | 57 | 0% | N/A | N/A |
#4 | $3.7M | 45 | -24% | N/A | N/A |
#5 | $0.2M | 3 | N/A | N/A | N/A |
#6 | $10.9M | 107 | -8% | N/A | N/A |
#7 | $19.3M | 172 | N/A | N/A | N/A |
#8 | $18.2M | 162 | 7% | N/A | N/A |
#9 | $33M | 294 | 5% | N/A | N/A |
#10 | $44.4M | 348 | 0% | N/A | N/A |
What Is Auckland UniServices?
Auckland UniServices Limited is the commercial research, knowledge transfer and custom education company of the University of Auckland - dedicated to connecting the University’s capabilities to business and investors, Government and the community.
keywords:N/A
N/A
Total Funding
294
Number of Employees
$33M
Revenue (est)
5%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Auckland UniServices News
2022-04-06 - Pandemic propels global effort to study rare vaccine side effects
Bruce Carleton, a clinical pharmacologist at the University of British ... from Petousis-Harris's university and Auckland UniServices Ltd.,...
2022-04-06 - Global Dysthymia Clinical Trial Market 2022 Growth Analysis ...
Auckland UniServices; Columbia Northwest Pharmaceuticals; New York State Psychiatric Institute; University Of Washington; Centre For Addiction...
Other Companies in Sydney
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $105.1M | 294 | -2% | N/A |
#2 | $80.4M | 297 | N/A | N/A |
#3 | $108.2M | 298 | 21% | N/A |
#4 | $106.6M | 300 | 3% | N/A |
#5 | $95.6M | 301 | 5% | N/A |